Vaccines Safety during Emerging Infections and Issues of Special Populations and Minority Groups
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1845
Special Issue Editors
Interests: quality and safety; pharmaceutical and health policy; medical and pharmacy education; evidence-based practice; evaluating effectiveness and outcomes; users’ satisfaction; agreements between information sources; writing ethics and skills; tobacco control
Interests: emerging infectious diseases; one-health and zoonotic diseases; field epidemiology and outbreak investigation; public health emergencies; medical education; evidence-based practice; evaluating effectiveness and outcomes
Interests: pharmacovigilance; clinical pharmacy practice; pharmacy education and global health
2. AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates
Interests: pharmacotherapy; pharmacy practice; cardiology; adherence; hypertension; heart failure
Special Issue Information
Dear Colleagues,
During the last two decades, emerging infections have represented a significant global public health challenge. They are complicated, quickly and widely spreading, continuously changing, and highly impactful. Vaccines are one of the most effective measures to control the spread of such infections and reduce their effects on humans and societies. Vaccine safety is of high concern and represents a global agenda which is normally assessed via preclinical studies and clinical trials before such vaccines are approved for use. Following this, other measures, such as post-marketing surveillances, pharmacovigilance activities and pharmacoepidemiologic research, are used to ensure safety and monitor possible risks not discovered during early studies. However, certain special populations and minority groups are overlooked during such processes and steps. For example, infants, children, the elderly, patients with comorbidities, organ-damaged patients and some minority groups are not included in clinical trials, and they are likely to be ignored in large epidemiologic research normally focused on general populations. Such disadvantaged groups are treated like the general population during pandemics and outbreaks and thus subjected to vaccine intake, and some of these groups represent a priority for vaccination. Those groups are likely more prone to the adverse and side effects of vaccines and are more affected by the diseases themselves. The new technologies used in vaccine production also pose a source of extra risk since they have not been tested sufficiently. The issue of vaccine safety is a high priority of the 21st Century and is predicted to be a main concern for at least the coming twenty years.
Objectives:
Papers specifically aiming to achieve one of the following objectives are welcomed, as they represent the editors’ main interest, but they should not be restricted to these objectives alone. The editors will evaluate the scope and purpose of submitted papers.
- How to communicate vaccine-related safety issues;
- Policy making and regulations related to vaccine safety;
- How to report vaccine-related pharmacovigilance;
- How to manage vaccine side effects and adverse reactions;
- Companies versus labs versus government communications regarding vaccine safety.
Examples of special populations:
Elderly; infants; children; patients with genetic problems; patients with autism; pregnancy; patients with cancer; patients with disabilities; patients with organ damage; patients with comorbidities.
Targeted Minority Groups:
Restricted to ethnic and religious-related minority groups.
Targeted emerging infections:
- SARS;
- COVID-19;
- Nipah virus;
- Dengue virus;
- Ebola virus;
- Zika virus;
- Hepatitis;
- Monkeypox virus.
Targeted Types of papers:
All the following types of articles are welcomed:
- Clinical trials;
- Epidemiology studies;
- Health system research;
- Surveillances;
- Systematic reviews;
- Narrative reviews;
- Expert opinions;
- Perspectives;
- Secondary data;
- Big data (e.g., social-media-related);
- Stakeholders’ and societies’ perceptions.
Dr. Ahmed Ibrahim Fathelrahman
Dr. Elmoubashar Farag
Dr. Mansour Adam Mahmoud
Dr. Asim Ahmed Elnour
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine safety
- emerging infections
- special populations
- minority groups
